If you look at the task that was given to us—and we all certainly embraced it—you see that it was quite monumental. Here we were to provide advice on securing vaccines that did not exist yet. They were not licensed; they were still in the clinical trial stage. We reviewed a lot of companies and a lot of vaccine candidates. I think there were over 200 that we had some data on. We whittled that list down, as a task force, into those that we thought were of primary interest. We invited a number of those companies in to present to us and we had a back and forth....
As Joanne said in her opening comments, the capabilities of the people on this task force, I would say, are second to none in the world. When we engaged in debate and discussion with the companies, we were able to get, as best we could, to the heart of the data.
If you look back, you'll see that we recommended procuring vaccines before they were actually licensed in Canada. As for the seven vaccines that we recommended, none of them had even been approved and none had finished clinical trials. If we look at where we are now the, we see that the first four vaccines were all vaccines that we recommended. So far, it's four for four.